GlassScriptPhysician profile
Amy Chanda Miller
NPI 1265533038
$82,346.06
in general payments reported to CMS, 2019-2025
24 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,402 · 2020: $2,408 · 2021: $15K · 2022: $16K · 2023: $19K · 2024: $5,111 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $3,141 · Travel and Lodging: $1,850 · Consulting Fee: $1,760 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,450.00 |
| Food and Beverage | $3,140.71 |
| Travel and Lodging | $1,850.35 |
| Consulting Fee | $1,760.00 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $71,043.42 | 2021-2025 | |
| Allergan, INC. | $4,434.79 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,830.03 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $767.13 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $679.85 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $604.59 | 2019-2023 | Austedo Xr, Uzedy |
| Lundbeck LLC | $422.23 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $230.02 | 2022-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $212.67 | 2020-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $186.21 | 2023-2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $179.99 | 2019-2023 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $115.33 | 2022-2025 | Quviviq, Quviviq |
| Sunovion Pharmaceuticals INC. | $93.86 | 2019-2020 | |
| Tris Pharma INC | $78.94 | 2023-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $78.36 | 2022-2025 | Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $68.49 | 2019 | |
| Neurocrine Biosciences, INC. | $66.44 | 2022-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $64.64 | 2020-2021 | |
| Neuronetics, INC. | $47.12 | 2019 | |
| Eisai INC. | $44.02 | 2021 | |
| Merck Sharp & Dohme LLC | $34.36 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $32.89 | 2025 | Jornay Pm |
| Corium, LLC | $18.74 | 2024 | Azstarys |
| Adlon Therapeutics L.P. | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.